NRx Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company developing novel therapies for neurodegenerative, neuropsychiatric and infectious diseases. The company's core technology platforms include nanocatalytic gold particles and proprietary small‐molecule compounds designed to modulate cellular energy metabolism, reduce oxidative stress and restore immune balance. NRx is advancing multiple candidates through preclinical and clinical development with the goal of addressing unmet medical needs in conditions ranging from amyotrophic lateral sclerosis (ALS) and Parkinson’s disease to bipolar depression and post‐traumatic stress disorder (PTSD).
The company’s lead program, CNM‐Au8, is a stable nanocrystal formulation of gold designed to catalyze neuronal bioenergetics and provide antioxidant activity. CNM‐Au8 is being evaluated in Phase II trials for ALS (REVITALISE) and Parkinson’s disease (RESCUE‐PD). In parallel, NRx is developing NRX‐101, an oral fixed‐dose combination intended to treat acute suicidal ideation and behavior in bipolar depression, and NRX‐102 for PTSD. The pipeline also includes TheraKine, an immunomodulatory cytokine formulation being explored for hospitalized COVID-19 patients, and additional anti‐inflammatory assets in earlier stages of research.
Founded to commercialize assets licensed from third‐party research organizations, NRx Pharmaceuticals is headquartered in the United States and serves patients and healthcare markets in North America, Europe and beyond. The company’s strategy centers on advancing its lead candidates through pivotal trials, securing regulatory designations where possible, and forming partnerships to support late‐stage development and eventual commercialization. NRx is led by a management team with experience in drug development, regulatory affairs and commercial strategy, and is publicly traded on the Nasdaq Capital Market under the symbol NRXPW.
AI Generated. May Contain Errors.
